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Introduction        
INTRODUCTION 
            Drug utilization research is an essential part of pharmacoepidemiology as it 
describes the extent, nature and determinants of drug exposure. Drug use is a complex 
process. In any country, a large number of socio-cultural factors contribute to the way 
drugs are prescribed. (Sachdeva and Patel,2010) 
 
Drug utilization evaluation can be used for the description of drug use pattern; 
early signals of irrational use of drugs; interventions to improve drug use; quality control 
cycle and continuous quality improvement. The principal aim of drug utilization research 
is to facilitate the rational use of drugs in populations, (Pandey et al.,2010).  For the 
individual patient, the rational use of a drug implies the prescription of a well 
documented drug at an optimal dose, together with the correct information, at an 
affordable price. Drug utilization research in itself does not necessarily provide answers, 
but it contributes to rational drug use in important ways as described below. 
 
Drug utilization research can increase our understanding of how drugs are being 
used as follows. 
• It can be used to estimate the numbers of patients exposed to specified drugs 
within a given time period. Such estimates may either refer to all drug users, 
regardless of when they started to use the drug, or focus on patients who started 
to use the drug within the selected period. 
• It can describe the extent of use at a certain moment and/or in a certain area. Such 
descriptions are most meaningful when they form part of a continuous evaluation 
system, i.e. when the patterns are followed over time and trends in drug use can 
be discerned. 
• Researchers can estimate to what extent drugs are properly used, overused or 
underused. 
• It can determine the pattern or profile of drug use and the extent to which 
alternative drugs are being used to treat particular conditions. 
• It can be used to compare the observed patterns of drug use for the treatment of a 
certain disease with current recommendations or guidelines.(WHO,2003) 
 
This study investigates the prescription pattern of corticosteroids for COPD, 
Asthma and Allergic Rhinitis; including the demographic variations in their use. The 
study aims to answer the following questions: 
 
 How does the use of corticosteroids vary with demographic factors, namely age, 
sex, socioeconomic status and locality of residence? 
 What are the different types of steroids prescribed, its dose and route of 
administration? 
 Difference in corticosteroids used in various disorders.  
 How does the use of corticosteroids vary with severity of disease?  
 
             Corticosteroids are very potent drugs that are known for their anti-inflammatory, 
anti-proliferative and immunosuppressive effects. Corticosteroids are often called as 
“steroids”; they greatly improve symptoms and provoke impressive results in different 
number of conditions, (Satku, 2006).   Due to their powerful anti inflammatory and 
immunosuppressive actions, these drugs are being prescribed widely by physicians 
(Ankit and Bharat, 2010). 
 
 
 
This study is aimed to measure corticosteroid use in a health facility that will 
describe drug use pattern and prescribing behavior. The patterns of drug use in a hospital 
setting need to be monitored intermittently in order to analyze their rationality and to 
offer feedback to drug prescribers so as to enable and effect suitable modifications in 
prescribing pattern to increase the therapeutic benefits and reduce adverse effects. 
(Kumar et al., 2011) 
 
   
 
  
  
 
 
 
 
 
 
 
 
 
Review of Literature  
 
REVIEW OF LITERATURE 
 
Drug utilization audits are qualitative assurance programs to ensure that drugs are 
used correctly and safely. The nature of such audits can be quantitative or qualitative or 
combination of both. Quantitative audits are concerned with quantifying various facts of 
drug therapy use within health care system whereas qualitative audits compare drug use 
or practice with predetermined standards or criteria. (Pandey et al., 2010)  
 
There are only some studies which evaluated trends in prescribing of inhaled 
corticosteroids for asthma and patterns of prescribing in relation to selected physician 
characteristics. The percent of physicians prescribing an inhaled corticosteroid increased 
over time with consistently greater prescribing among specialists. Annual comparisons 
by specialty groups revealed that specialists prescribed inhaled steroids to a larger 
proportion of their patients than generalists. (Allen Ramey et al., 2003) 
 
Utilization pattern of glucocorticosteroid drugs with special emphasis on their 
adverse effects in a tertiary care teaching rural hospital, attached to a medical college, 
showed that dexamethasone dipropionate ,budesonide , and prednisolone  were used 
predominantly in conditions like bronchial asthma, COPD, bronchiectasis, 
photodermatitis. Most frequent adverse drug reactions observed were muscular weakness 
and insomnia. Use of glucocorticoid drugs was found appropriate and as per standard 
guidelines and current protocol of prescribing glucocorticoid drugs. It was also found 
that there is over prescribing of the drugs to the patients. So the special attention of all 
doctors and clinical pharmacists is needed to work together to establish a rational, and 
practical protocol for clinical conditions. (Ankit  and Bharat, 2010) 
A study was carried out to find out prescribing pattern of corticosteroids in 
dermatology department of a tertiary care teaching hospital. The study revealed that 
topical corticosteroids of very potent groups were commonly prescribed and prescribing 
information was adequate in majority of the cases. This report was aimed for the benefit 
of the patients, providing feed back to the prescribers and desirable in rationalizing 
prescribing practices. (Kumar et al., 2011) 
 
Inhaled corticosteroids (ICS) are more effective in COPD patients when used 
with Long-Acting Beta2-Adrenergic Receptor Agonist than with Short-Acting Beta2-
Adrenergic Receptor Agonist. Adding long-acting beta agonists to inhaled 
corticosteroids has been associated with beneficial effects in COPD patients in 
randomized controlled trials and observational studies. However ,it is not known whether 
adding short-acting beta agonists to ICS instead of will be similarly effective in COPD. 
The effectiveness of combination therapies involving ICS with LABA versus ICS with 
SABA in reducing risk of re-hospitalization or death among COPD patients within a year 
of discharge from a first COPD hospitalization was studied (Bettoncelli et al., 2005). 
 
In a study, on the corticosteroid-prescribing patterns of primary care sports 
medicine physicians to look for common indications. Fifty-eight of the physicians 
reported prescribing oral corticosteroids for musculoskeletal injuries. Prednisone was the 
corticosteroid prescribed most of the physicians. The average prescription length was 7 
days. One half of the physicians tapered the dose. The most common starting dose was 
60 mg. Despite little evidence to support their use, primary care sports medicine 
physicians commonly prescribe corticosteroids. (Kimberly, et al., 2002) 
 
Topical corticosteroids are widely used in the treatment of skin diseases. Pattern 
of topical corticosteroids prescribing and the relation of patient and prescriber attributes 
to the type of corticosteroid preparation prescribed have been studied and found that 
dermatologists were more likely to prescribe very high potency steroids than were other 
physicians. Physicians other than dermatologists were more likely than dermatologists to 
prescribe combination agents containing moderate-or high-potency topical 
corticosteroids and an anti infective agent. The pattern of topical corticosteroid 
prescribing is substantially different for dermatologists and other physicians. These 
differences may reflect differences in severity or complexity of the disease or differences 
in prescribing habits. (  Stem  et al.,1996) 
 
A study was carried out to find comparative cost-effectiveness of a fluticasone-
propionate/salmeterol combination versus anticholinergics as initial maintenance therapy 
for chronic obstructive pulmonary disease. In this retrospective study observational 
sample of COPD patients ,initiating treatment with fluticasone-propionate/salmeterol 
combination was associated with significantly better clinical and economic outcomes 
compared with short and long-acting anticholinergic  therapy. Consistent with the goal of 
preventing and reducing exacerbations advocated by global guidelines, the finding 
suggest that initiation of maintenance treatment with fluticasone-propionate/salmeterol 
combination may afford clinical benefits at a lower cost than anticholinergic treatment. 
(Dalal  et al.,2010) 
 
Another study investigated the pattern of use of medications for asthma in 
Australia including the demographic variation in their use. In the population, use of both 
inhaled corticosteroids and long-acting beta agonists increased with age. Use of inhaled 
corticosteroids and long acting beta agonists was slightly higher in females when all ages 
were combined. Many people for whom asthma management guidelines would 
recommend using inhaled corticosteroids were not using them regularly. At the same 
time, most inhaled corticosteroids that were dispensed to adults were in the strongest 
formulation, which may add to the risk of harmful side effects. (Ampon  et al., 2006) 
 
A study carried out to assess the prescription patterns of asthma medication for 
children revealed that in general practice the number of prescriptions per child issued for 
asthma is relatively low. Continuous medication with a bronchodilator and/or a 
corticosteroid was prescribed in children. Asthma medications other than bronchodilators 
or corticosteroids were prescribed relatively low. One in 20 children was prescribed 
bronchodilators only continuously, indicating room for improvement.(Uijen et al., 2011) 
 
Endogenous corticosteroids are a class of steroid hormones that are produced in 
the adrenal cortex. Corticosteroids are involved in a wide range of physiologic systems 
such as stress response, immune response and regulation of inflammation, carbohydrate 
metabolism, protein catabolism, blood electrolyte levels, and behavior. The principal 
adrenal steroids are the glucocorticoids and mineralcorticoids. In humans, cortisol 
(hydrocortisone) is the main glucocorticoid and aldosterone is the main 
mineralocorticoid. (Goodman and Gilman ,2006). 
 
GLUCOCORTICOIDS 
 Adrenal steroids are synthesized and released by Adrenocorticotropic Hormone, 
which is secreted from the anterior pituitary gland. Adrenocorticotropic Hormone 
secretion is regulated partly by CRF derived from the hypothalamus and partly by the 
level of glucocorticoids in the blood. (Rang and dale, 2005) 
• Action on the mediators of inflammatory and immune responses: These include:  
• Decreased production of prostanoids owing to decreased expression of 
cyclooxygenase-2  
• Decreased generation of cytokines-IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, TNF-γ 
and cell adhesion factors , granulocyte-macrophage colony-stimulating factor 
through inhibition of transcription of the relevant genes  
• Reduction in the concentration of complement components in the plasma  
• Decreased generation of induced nitric oxide   
• Decreased histamine release from basophils  
• Decreased IgG production( MacIntyre,2006) 
MINERALOCORTICOIDS 
Mineralocorticoid is aldosterone, which is produced in the outermost of the three 
zones of the adrenal medulla, the zona glomerulosa. Its main action is to increase Na
+
 
reabsorption by an action on the distal tubules in the kidney, with concomitant increased 
excretion of K
+
 and H
+. 
An excessive secretion of mineralocorticoids , causes marked 
Na
+
 and water retention with resultant increase in the volume of extracellular fluid, 
hypokalemia, alkalosis and hypertension. A decreased secretion, as in Addison's disease, 
causes increased Na
+
 loss. The control of the synthesis and release of aldosterone 
depends mainly on the electrolyte composition of the plasma and on the angiotensin II 
system. Low plasma Na
+
 or high plasma K
+
 concentrations affect the zona glomerulosa 
cells of the adrenal directly, stimulating aldosterone release. Depletion of body Na
+
 also 
activates the renin-angiotensin system. One of the effects of angiotensin II is to increase 
the synthesis and release of aldosterone. (Rang and dale,2005) 
 
 
 
USE OF CORTICOSTEROIDS 
The use of corticosteroids started some 50 years ago. Being very powerful anti-
inflammatory agents, they were described as impressive drugs as they not only improved 
certain clinical conditions, but also conferred a subjective sense of well-being.  
Corticosteroids have been used commonly in the fields of rheumatology, orthopaedics, 
dermatology, oncology, respiratory medicine, ENT and ophthalmology. Endocrinology 
utilizes corticosteroids for hypoadrenalism and tapering regimes in hypothalamic-
pituitary adrenal axis suppression. While powerful as anti-inflammatory agents, these 
medications have a host of systemic effects which are harmful to the patient. Hence, care 
should be exercised in the indications, route of administration and duration of treatment. 
The latest development towards greater safety of corticosteroids usage with preservation 
of full efficacy is channeled at the glucocorticoid receptor so that reduced potency in side 
effects is possible. These new insights may pave the way for novel, safer therapies that 
retain the efficacy of currently prescribed steroids. (Ankit  and Bharat .,2010) 
Steroids can be prescribed as: 
• Topical steroids 
• Intranasal steroids 
• Inhaled corticosteroids 
• Steroid ear and eye drops 
• Intra-articular steroid injections 
• Oral steroids   ( Satku,2006)               
 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
Chronic obstructive pulmonary disease (COPD) constitutes an important public 
health issue, with a high prevalence and global morbidity and mortality (Miguel-Dı´ez et 
al., 2011). COPD is a progressive inflammatory disease affecting the airways of the 
lungs along with irreversible airflow obstruction (MacIntyre, 2006). It can be classified 
into emphysema and chronic bronchitis. According to the World Health Organization 
(WHO), the disease affects 210 million people worldwide and it mainly occurs in about 
10% of the population above the age of 40 years. In 1990 the sixth commonest global 
cause of death was COPD, currently fourth in developed countries and by 2020 it is 
expected to rise to third place globally (Suissa and Barnes , 2009).  
 
If the disease is prominent in the proximal airways, symptoms of cough and 
phlegm predominate (chronic bronchitis). Similarly, if the disease is prominent in the 
distal small-airway regions of the lung, there may be concomitant alveolar destruction 
and the sensation of dyspnea may predominate. The most common cause of COPD is 
tobacco smoke exposure, although a small percentage of COPD patients are never-
smokers and are thought to develop chronic airway inflammation and alveolar 
destruction from genetically determined impaired airway defenses (MacIntyre, 2006) .In 
the treatment regimen of COPD apart from inhaled beta agonists and anticholinergics, 
corticosteroids can also play a important role. 
 
The management guidelines of COPD recommend drug treatment in the form of 
short-acting inhaled bronchodilators, followed by long-acting agents in patients with 
persistent symptoms. The addition of inhaled corticosteroids is indicated for patients 
with severe or very severe COPD (FEV1>50% of the reference value) and also in 
repeated exacerbations, since these drugs have been shown to decrease the number of 
exacerbations and improve both quality of life and lung function in these individuals ( 
Miguel-Dı´ez et al., 2011). In addition, a recent study in patients with FEV1 >60% of the 
reference value , has conﬁrmed the positive impact of combining inhaled glucocorticoids 
and long-acting beta –adrenergic agonists upon these same parameters (Calverley  et al., 
2007) The rest of COPD patients cannot beneﬁt from inhaled corticosteroids, and may 
experience side effects from their  use. 
 
Although cigarette smoking is the major risk factor for COPD, occupational 
exposure and environmental pollutants are also implicated. Genetic factors also play an 
important in determining which exposed individuals will develop COPD. A significant 
example is alpha1-antitrypsin deficiency. In susceptible individuals, exposure to noxious 
gases or particles can result in chronic inflammation with tissue injury, ineffective repair 
and structural changes. These changes occur in central and peripheral airways, lung 
parenchyma and pulmonary vasculature. Subsequent to these changes, hypoxemia and 
alveolar hypoventilation can occur.Increased inflammation, often triggered by infection, 
may result in further physiological comprise and clinical exacerbations. 
 
By altering gene transcription and protein synthesis inhaled corticosteroids 
reduce airway inflammation. COPD is relatively corticosteroid resistant possibly because 
it is predominantly a neutrophilic inflammatory disease. Guidelines recommend inhaled 
corticosteroids in patients with frequent exacerbations or those who have severe disease 
(FEV1<50%) and remain symptomatic despite inhaled long-acting bronchodilator use. 
Clinical and physiological effects may include a reduction in symptoms and exacerbation 
frequency, and improvement in health status and FEV1. Some trials of inhaled 
corticosteroids have raised questions about data analysis and an absence of true 
intention-to-treat analysis in some of the studies. Further analysis of recent studies may 
be needed to clarify the true role of inhaled corticosteroids in COPD. Overall, there are 
few data about back-titrating of corticosteroids (Malipatil and McDonald , 2009) Ten to 
thirty per cent of the total dose of inhaled corticosteroids is systemically absorbed 
because of absorption from the lung. Quantifying the risk of systemic adverse effects is 
challenging given confounding factors such as co morbidities, oral corticosteroid use and 
the systemic effects of COPD. This balance of benefits versus adverse effects may be 
important in the elderly who are at risk of co morbidities. Local adverse effects include 
oral candidiasis and dysphonia.  
 
ALLERGIC RHINITIS 
Allergic rhinitis (AR) is a common disease affecting large population and may 
cause significant social and economic impact if they are not managed appropriately. 
Allergic rhinitis can be defined as the inflammation of the nasal mucosa, induced by 
exposure to allergens after sensitization; triggered by an immunoglobulin E-mediated 
inflammatory response that can result in chronic or recurrent symptoms. Allergic rhinitis 
may be also called as seasonal allergic rhinitis. Seasonal rhinitis occurs in response to 
specific allergens usually present at predictable times of the year, during plants‟ 
blooming seasons. Seasonal allergens include pollen from trees, grasses, and weeds. 
Perennial allergic rhinitis is a year-round disease caused by nonseasonal allergens, such 
as house-dust mites, animal dander, and molds, or more allergic sensitivities. 
(McCroryet al., 2003) 
 
Allergic rhinitis is always associated with several other serious medical 
conditions, including asthma, rhino-sinusitis, otitis media, nasal polyposis, respiratory 
infections, and orthodontic malocclusions (Plaut and Valentine, 2005).
 
The 
development of allergic rhinitis is determined by genetics, allergen exposure, and the 
presence of risk factors. A family history of allergic rhinitis, atopic dermatitis, or asthma 
suggests that rhinitis is allergic. Allergen exposure is another necessary factor. For 
allergic rhinitis to occur, an individual must be exposed over time to a protein that elicits 
the allergic response in that individual (Marshall  et al., 2001).
 
Allergic reactions in the nose are mediated by antigen-antibody responses, during 
which allergens interact with specific IgE molecules bound to nasal mast cells and 
basophils. In allergic people, these cells are increased in both number and reactivity. 
During inhalation, airborne allergens enter the nose and are processed by lymphocytes, 
which produce antigen-specific IgE, thereby sensitizing genetically predisposed hosts to 
those agents. Upon nasal re-exposure, IgE bound to mast cells interacts with airborne 
allergen, triggering release of inflammatory mediators. (Wilson  et al., 2000). 
 
Bronchitis can develop as a result of allergic rhinitis because of excess fluid in 
the chest. Bronchitis is an infection in the lungs that causes the airways to swell, causing 
asthma-like symptoms, such as difficulty in breathing, wheezing and shortness of breath. 
 Topical glucocorticoids, including beclomethasone, budesonide, flunisolide, 
fluticasone and triamcinolone, can be highly effective with minimal side effects, 
particularly if treatment is instituted immediately prior to the allergy season. Topical 
glucocorticoids can be administered twice daily (beclomethasone and flunisolide) or 
even once daily (budesonide, mometasone, fluticasone, and triamcinolone). 
 
Nasal steroids are an excellent choice for treating perennial rhinitis, and can be 
useful in seasonal rhinitis, especially if begun in advance of symptoms. ( Weiner                   
et al., 1998) Nasal steroids appear to be effective with minimal adverse effects. Some 
believe that nasal steroids should be recommended as initial therapy over antihistamines 
because of their high level of efficacy when used properly and along with avoidance of 
allergens.( Quintiliani,1996) Multiple mechanisms are involved with the effects of nasal 
steroids on the nasal mucosa: reducing inflammation by reducing mediator release, 
suppressing neutrophil chemotaxis, reducing intracellular edema, causing mild 
vasoconstriction, and inhibiting mast cell-mediated late-phase reactions.(Mehle , 2003) 
Topical steroids produce only minor adverse effects, most commonly sneezing, stinging, 
headache, and epistaxis. Despite concerns about safety of systemic steroids, nasal 
steroids have been found to have no significant association with hypothalamic–pituitary 
axis suppression, cataract formation, glaucoma, or bone mineral density changes in the 
doses used for allergic rhinitis. (Adams et al., 2002) 
 
ASTHMA
 
Asthma is a chronic disease of the airway inflammation and airflow obstruction 
characterized by symptoms such as wheezing, breathing difficulty, chest tightness and 
cough along with bronchial hyper-responsiveness. In India 3-5% and 3-11% of the 
pediatric and adult population respectively is affected by asthma.( Pandey et al., 2010)  
            Long term treatment is required for the effective management of the disease. 
Asthma is associated with airway inflammation, airway hyper-reactivity, and acute 
bronchoconstriction. Glucocorticoids do not directly relax the airway smooth muscles 
and thus have little effect on acute bronchoconstriction. The anti-inflammatory effects of 
glucocorticoids in asthma include modulation of cytokine and chemokine production; 
inhibition of eicosanoid synthesis; marked inhibition of accumulation of basophils, 
eosinophils, and other leukocytes in lung tissue; and decreased vascular permeability.  
(MacIntyre,2006)   
Systemic Glucocorticoids are used for acute asthma exacerbations and chronic 
severe asthma. Significant doses of glucocorticoids (e.g., 40 to 60 mg prednisone or 
equivalent daily for 5 days; 1 to 2 mg/kg per day for children) are often used to treat 
acute exacerbations of asthma. Previously, alternate-day therapy with oral prednisone 
was employed commonly in persistent asthma. Now most patients with asthma are better 
treated with inhaled glucocorticoids.. There are currently five glucocorticoids available 
for inhalation therapy: beclomethasone, dipropionate, triamcinolone acetonide, 
flunisolide, budesonide, and fluticasone propionate. The newer, highly potent drugs 
(e.g., fluticasone, flunisolide, and budesonide) can be effective with as little as one or 
two puffs administered twice or even once daily. Important variables that influence the 
effective dose include the severity of disease, the particular steroid used, and the device 
used for drug delivery, which determines the actual quantity of drug delivered to the 
lungs.(Goodman and Gilman,2006) 
 
  
  
 
 
 
 
 
 
 
 
 
Methodology   
 
METHODOLOGY 
Aim  
          To analyze the prescribing patterns of corticosteroid drugs in the pulmonology 
department of  a tertiary care hospital. 
Study design 
          It was a prospective study. 
Study setting 
          The study was conducted in the Department of Pulmonology and Sleep Medicine 
Kovai Medical Center and Hospital in Coimbatore, Tamil Nadu. 
Study period 
          The study was conducted over a period of six months from June 2011 to December 
2011. 
Study criteria 
Inclusion criteria 
         Patients with COPD, asthma and allergic rhinitis, attending the pulmonology clinic 
who receives corticosteroid drugs as their treatment plan. 
Exclusion criteria 
          Patients with COPD, asthma and allergic rhinitis, attending the pulmonology clinic 
who are not receiving corticosteroids. 
Sources of data 
          The data was collected from various sources such as patient‟s case reports and 
treatment charts. 
Study protocol 
           Patients who met the study criteria were identified. Demographic details, different 
corticosteroids prescribed and their dose and route of administrations were noted.  
Severity of the asthma and COPD were classified based on GINA and GOLD guidelines 
respectively. 
Severity of disease 
          The GOLD and GINA guidelines for assessing the severity of COPD and asthma 
respectively, were used to assess the same.  
Statistical analysis 
            Demographic characteristics have been expressed as percentages.  Analysis of the 
relationship between variables was compared by using chi square test and the p value              
≤ 0.05 was taken to be significant.  All statistical data was assessed by using SPSS                  
(v-16.0). 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
Results  
 
RESULTS 
In this Prospective study, the prescribing patterns of corticosteroid drugs was 
evaluated in a total of 108 prescriptions  in the pulmonology department  in a tertiary 
care hospital, during the period June  2011 to December 2011. 
  Among corticosteroid prescriptions, 58 (53.7%) were males and 50(46.3%) were 
females (Table 1, Figure 1). Highest number of prescriptions (25 out of 108) were 
belonging to the age group of 60-69 years (23.14%)  and lowest number of prescriptions 
(4 out of 108) were belonging to the age group of 10-19 years (3.7%). (Table 2,                       
Figure 2). 
  Among total corticosteroid prescriptions, 23 (21.3%) were inpatients and 
85(78.7%) were outpatients (Table 3, Figure 3).The total study population were 
categorized into four group on the basis of diagnosis. It was given as Asthma, COPD, 
Allergic Rhinitis & Allergic Rhinitis + Asthma with percentage population of 37.96%, 
33.33%, 19.44% & 9.25% respectively. (Table 4, Figure 4). 
Most of the prescriptions containing corticosteroid were made for patients 
coming from urban and industrial polluted areas like Coimbatore (35.18%) and Tirupur 
(22.22%). (Table 5, Figure 5). Out of 108 prescriptions, 84 prescriptions were given to 
patients who were free from co-morbidity. Remaining 24 patients were diagnosed with 
more than one disease (co-morbid condition). (Table 6, Figure 6). 
Most common route of administration was dry powder inhaler (67.2%) followed 
by MDI (16.8%), Nasal spray (10.4%), and Oral (5.6%) respectively. (Table 7, Figure 7). 
Most commonly prescribed drug was Budesonide + Formoterol  (78.4%)combination 
whereas Budesonide(2.4%)  alone was less commonly prescribed. (Table 8, Figure 8). 
Budesonide + Formoterol  200 mcg combination was given in 37 prescriptions 
and 400 mcg was given in 61 prescriptions(Table 9, Figure 9). Budesonide 100 mcg 
containing 0ne prescription out of 108  prescriptions and Budesonide 200 mcg 
containing two prescriptions in the total prescriptions(Table 10, Figure 10).Oral route of 
prednisolone 20 mg and 30 mg containing 3 and 4 prescriptions respectively.( Table 11, 
Figure 11). Fluticasone+Salmeterol  50,100 and 200 mcg combination containing  1,1 
and 2 prescriptions  respectively. (Table 12, Figure 12).  
Median route of administration in Asthma, COPD and Allergic Rhinitis +Asthma 
prescription was dry powder inhaler. The most prominent route of administration was 
nasal spray in Allergic Rhinitis prescriptions. (Table 13). Median drug of administration 
in Asthma , COPD  and Allergic Rhinitis +Asthma prescription was Budesonide + 
Formoterol - 36(87.80%) , 35(97.22%), 8(80%) respectively. The most prominent drug 
of administration in Allergic Rhinitis was Mometasone furoate 13(61.90%)(Table 14, 
Figure 14). 
Budesonide + Formoterol 200 mcg combination was prescribed in 5 and 400 mcg 
was prescribed in 31 of the total 41 Asthma prescriptions. (Table 15, Figure 15). 
Our study revealed that  majority of the COPD patients, were  smoker (52.77%) 
and 16.66% had a history of smoking (Table 16, Figure 16).Eleven(11) prescriptions had 
Budesonide + Formoterol  200 mcg and  24 prescription had Budesonide + Formoterol  
400 mcg in the total 36 COPD prescriptions. (Table 17, Figure 17).Oral route of 
prednisolone 20 mg containing two prescriptions and prednisolone 30 mg containing 
three prescriptions in the total 36 COPD prscriptions. (Table 18, Figure 18). 
The most prominent Allergic Rhinitis drug was Budesonide + Formoterol  200 
mcg combination(73.68%) in 21 Allergic Rhinitis prescriptions. (Table 19, Figure 19). 
Allergic Rhinitis +Asthma prescriptions had Budesonide + Formoterol  200 mcg 
combination in 3 and Budesonide + Formoterol  400 mcg combination in 5 of the total 
21 prescriptions. (Table 20, Figure 20). One each prescription of Budesonide 100 mcg 
and Budesonide 200 mcg were prescribed  in the total Allergic Rhinitis +Asthma  
prescriptions(n=10)(Table 21, Figure 21). 
  Most common drug prescribed to IP patients was Budesonide + Formoterol  
combinations 43.33%  and less commonly prescribed drug was   Fluticasone+Salmeterol  
3.33%.(Table 22, Figure 22).Most general route of administration was 
Nebuliser(33.33%) and oral route of administration was less commonly prescribed(10%). 
(Table 23, Figure 23). 
In the study population, we found a significant relationship between age 
(p<0.007), gender (p<0.016), locality of residence (p<0.023) & socioeconomic status 
(p<0.016) and prescribing patterns of corticosteroids.(Table 24, Figure 24).There was a 
significant relationship with severity of disease such as COPD (p<0.008) and Asthma 
(p<0.011) and the prescribed corticosteroids. (Table 25, Figure 25). 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
Tables & Graphs  
 
TABLES AND GRAPHS  
 
TABLE 1  : Gender wise distribution of total prescriptions. 
 
Sl. No Gender No. of prescriptions Percentage (%) 
1. Male 58 53.7 
2. Female 50 46.3 
 
 
 
FIGURE 1  : Gender wise distribution of total prescriptions. 
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TABLE 2 : Age wise distribution of  the total prescriptions. 
Sl. No Age No. of prescription Percentage (%) 
1. 10-19 4 3.7 
2. 20-29 6 5.55 
3. 30-39 20 18.51 
4. 40-49 23 21.29 
5. 50-59 18 16.66 
6. 60-69 25 23.14 
7. 70-79 12 11.11 
 
 
FIGURE 2 : Age wise distribution of the total prescriptions. 
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TABLE 3 : Distribution of  the total prescriptions on the basis of inpatients(IP) and 
out patients(OP). 
Sl. No IP/OP No. of prescriptions Percentage (%) 
1. IP 23 21.3 
2. OP 85 78.7 
 
 
 
FIGURE 3 : Distribution of  the total prescriptions on the basis of inpatients(IP) 
and out patients(OP). 
 
 
TABLE 4 : Disease wise distribution of the total prescriptions. 
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Sl. No Disease No. of prescriptions Percentage (%) 
1. COPD 36 33.33 
2. AR 21 19.44 
3. Asthma 41 37.96 
4. AR + Asthma 10 9.25 
 
 
 
FIGURE 4 : Disease wise distribution of the total prescriptions. 
 
 
 
TABLE 5 : Distribution of the prescriptions on the basis of place of residence of                                                           
the     patients. 
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Sl. No Locality No. of prescription Percentage (%) 
1. Coimbatore 38 35.18 
2. Erode 9 8.33 
3. Dindugal 9 8.33 
4. Karur 5 4.62 
5. Salem 9 8.33 
6. Palakkad 8 7.4 
7. Tirupur 24 22.22 
8. Namakkal 6 5.55 
 
FIGURE 5 : Distribution of the prescriptions on the basis of place of residence of 
the patients. 
 
 
TABLE 6 : Co-morbidity wise distribution of the total study population. 
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Sl. No No. of co-morbidity No. of prescription Percentage (%) 
1. No disease 84 77.77 
2. 1 15 13.88 
3. 2 6 5.55 
4. 3 2 1.85 
5. >3 1 .92 
 
 
 
FIGURE 6 : Co-morbidity wise distribution of the total study population. 
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 TABLE 7 : Distribution of the total prescriptions on the basis of the route of 
administration of the corticosteroids. 
Sl. No Route No, of prescriptions Percentage (%) 
1. DPI 84 67.2 
2. MDI 21 16.8 
3. Nasal Spray 13 10.4 
4. Oral 7 5.6 
DPI     - Dry Powder Inhaler                                 
MDI    - Metered Dose Inhaler 
 
FIGURE 7 : Distribution of the total prescriptions on the basis of the route of 
administration of the corticosteroids. 
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TABLE 8 : Corticosteroids prescribed and their frequency in the study population. 
Sl. No Drug No, of prescriptions Percentage (%) 
1. Budesonide+Formoterol 98 78.4 
2. Budesonide 3 2.4 
3. Fluticasone+Salmeterol 4 3.2 
4. Mometasone furoate 13 10.4 
5. Prednisolone 7 8.6 
 
 
 
FIGURE 8 :Corticosteroids prescribed and their frequency in the study population.   
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TABLE 9 : Frequency of prescriptions in different doses of Budesonide in 
Budesonide + Formoterol combination(n=98). 
Sl. 
No 
Budesonide+Formoterol (mcg)  No. of prescriptions 
Percentage 
(%) 
1. 200 37 37.76 
2. 400 61 62.24 
 
 
FIGURE 9 : Frequency of prescriptions in different doses of Budesonide in 
Budesonide + Formoterol combination(n=98).
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TABLE 10 : Frequency of prescriptions under different doses of Budesonide(n=3). 
 
Sl. No Budesonide (mcg)  No. of prescriptions Percentage (%) 
1. 100 1 33.33 
2. 200 2 66.66 
 
 
 
FIGURE 10 : Frequency of prescriptions under different doses of Budesonide(n=3). 
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TABLE 11 : Frequency of prescriptions under different doses of Prednisolone(n=7). 
 
Sl. 
No 
Prednisolone (mg)  No. of prescriptions Percentage (%) 
1. 20 3 42.85 
2. 30 4 57.14 
 
 
 
FIGURE11: Frequency of prescriptions under different doses of Prednisolone(n=7). 
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TABLE 12 : Frequency of prescriptions in different doses of Fluticasone in 
Fluticasone + Salmeterol combination(n=4). 
Sl. 
No 
Fluticasone+Salmeterol (mcg) No. of prescriptions Percentage (%) 
1. 50 1 25 
2. 100 1 25 
3. 200 2 50 
 
 
 
FIGURE 12 :  Frequency of prescriptions in different doses of Fluticasone in 
Fluticasone + Salmeterol combination(n=4). 
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TABLE 13 : Median route of administration in the different disease conditions in 
the total prescriptions. 
 
Sl. No 
Disease(No. of 
prescriptions) 
Median Route 
No.of 
prescriptions. 
Percentage (%) 
1. Asthma(41) DPI 33 80.48 
2. COPD(36) DPI 21 58.33 
3. AR+Asthma(10) DPI 6 60 
4. AR(21) Nasal Spray 13 61.9 
 
 
 
 
 
 
 
 
 
TABLE 14 : Median drug of administration in the different disease conditions in 
the total prescriptions. 
Sl. 
No 
Disease(No. of 
prescriptions) 
Median Drug 
No.of 
prescriptions 
Percentage(%) 
1. Asthma(41) Budesonide+Formoterol 36 87.8 
2. COPD(36) Budesonide+Formoterol 35 97.22 
3. AR+Asthma(10) Budesonide+Formoterol 8 80 
4. AR(21) Mometasone furoate 13 61.9 
 
 
FIGURE 14 : Median drug of administration in the different disease conditions in 
the total prescriptions. 
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TABLE 15 : Dose wise distribution in the total prescriptions in the Asthma patients. 
Sl. 
No 
 
Budesonide+Formoterol (mcg) 
 
No. of prescriptions 
Percentage 
(%) 
1. 200 5 13.88 
2. 400 31 86.11 
 
 
 
FIGURE 15:Dose wise distribution in the total prescriptions in the Asthma patients. 
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TABLE 16 : Smoking habits of COPD patients (n=36) prescribed with 
corticosteroids. 
Sl. No Life style No. of prescriptions Percentage (%) 
1. Smoker 19 52.77 
2. Ex-smoker 6 16.66 
3. Non-smoker 11 30.55 
 
 
 
FIGURE 16 : Smoking habits of COPD patients (n=36) prescribed with 
corticosteroids. 
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TABLE 17 : Dose wise distribution in the total prescriptions in COPD 
patients(n=36). 
Sl. No 
Budesonide+Formoterol 
(mcg) 
No. of prescriptions Percentage (%) 
1. 200 11 31.42 
2. 400 24 68.57 
 
 
 
FIGURE 17 : Dose wise distribution in the total prescriptions in COPD 
patients(n=36). 
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TABLE 18 : Dose wise distribution in the total prescriptions in COPD 
patients(n=36). 
Sl. No 
Prednisolone 
(mg) 
No. of prescriptions Percentage (%) 
1. 20 2 40 
2. 30 3 60 
 
 
 
FIGURE 18 : Dose wise distribution in the total prescriptions in COPD 
patients(n=36). 
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TABLE 19 : Dose wise distribution in the total prescriptions in Allergic Rhinitis 
patients(n=21). 
Sl. No 
Budesonide+Formoterol 
(mcg) 
No. of prescriptions Percentage (%) 
1. 200 14 73.68 
2. 400 5 26.31 
 
 
 
FIGURE 19 : Dose wise distribution in the total prescriptions in Allergic Rhinitis 
patients(n=21). 
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TABLE 20 : Dose wise distribution in the total prescriptions in Allergic Rhinitis 
+Asthma patients(n=10). 
Sl. No 
Budesonide+Formoterol 
(mcg) 
No. of prescriptions Percentage (%) 
1. 200 3 37.5 
2. 400 5 62.5 
 
 
TABLE 20 : Dose wise distribution in the total prescriptions in Allergic Rhinitis 
+Asthma patients(n=10). 
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TABLE 21 : Dose wise distribution in the total prescriptions  in Allergic Rhinitis 
+Asthma patients(n=10). 
 
Sl. No Budesonide (mcg) No. of prescriptions Percentage (%) 
1. 200 1 50 
2. 400 1 50 
 
 
TABLE 21 : Dose wise distribution in the total prescriptions in Allergic Rhinitis 
+Asthma patients(n=10). 
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TABLE 22 : Drug  wise distribution in the total prescriptions of the IP patients. 
 
Sl. No Drug No. of prescriptions Percentage (%) 
1. Budesonide+Formoterol 13 43.33 
2. Budesonide 9 30 
3. Fluticasone+Salmeterol 1 3.33 
4. Prednisolone 3 10 
5. Hydrocortisone 4 13.33 
 
 
FIGURE 22 : Drug  wise distribution in the total prescriptions of the IP patients. 
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TABLE 23 : Route of administration wise distribution in the total prescriptions of 
IP patients. 
Sl. No Route No, of prescriptions Percentage (%) 
1. MDI 7 23.33 
2. NEB 10 33.33 
3. DPI 6 20 
4. Oral 3 10 
5. Injection 4 13.33 
 
 
FIGURE 23 : Route of administration wise distribution in the total prescriptions of 
IP patients. 
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TABLE 24 : Effect of various demographic factors on the prescribing patterns of 
corticosteroids. 
 
TABLE 25 : Effect of disease severity on the prescribing patterns of corticosteroids. 
  
  
 
 
 
 
 
 
 
 
 
Discussion   
 
DISCUSSIONS 
Glucocorticoid drugs are maximally utilized in disease related to the respiratory 
system. Respiratory conditions are usually allergic and inflammatory, where 
glucocorticoid drugs have a major role to play.  
 
The use of corticosteroid was higher in older people, compared with younger 
people, may be due to the presence of COPD in older persons. In older persons, these 
medications are commonly used to treat COPD (Allbon , 2007). However in our study 
also highest prescriptions were in the older age group.   
 
Different toxic exposures, differences in socioeconomic and living conditions, 
and differences in education levels also exist and may be responsible, at least in part, for 
the variations observed in the manifestations of respiratory disease (Miravitlles  et al, 
2008). Interestingly, significant heterogeneity was observed between sites, especially in 
women (Buist et al 2007). These differences can be observed among different areas of 
the same country, as was demonstrated in a Spanish study (Sobradillo et al 2000).  In 
our study most of the prescriptions containing corticosteroid were made for patients 
coming from urban and industrial polluted areas. 
 
The use and interpretation of spirometry in primary care (PC) in the diagnosis of 
chronic obstructive pulmonary disease (COPD) and to identify the treatment schedules 
administered found out that the number of drugs prescribed increased significantly with 
severity of the respiratory disease (Miravitlles  et al, 2007). There was a significant 
relationship between the disease groups, asthma and COPD, and IC prescription 
(Jackevicius et al, 1997). In our study also we identified that there was a significant 
relationship with severity of disease and the prescribed corticosteroids. 
 
The EPOCA study observed significant differences in the characteristics and 
management of the respiratory disease according to the socioeconomic status of the 
patients. It is important to point out the existing limitations for adequate classification of 
socioeconomic status among different countries. Treatment also showed some 
differences, with a higher use of old, cheaper, Short-Acting Beta2-Adrenergic Receptor 
Agonist and theophyllines and a lower use of tiotropium and combination therapy with 
LABA + ICS in patients of lower class and education (Miravitlles  et al, 2008). In our 
study population, we found a significant relationship between socioeconomic status and 
locality of residence and prescribing patterns of corticosteroids. 
 
Population distribution of asthma medication use identified that females were 
using more potent inhaled corticosteroids than males. In contrast to the findings in the 
population as a whole, those who were living in more disadvantaged areas used less 
potent inhaled corticosteroids (Allbon , 2007).  In our study we found out that males are 
using more corticosteroids. 
 
The respiratory medications were being used by COPD and Asthma patients at 
hospital admission. Most patients used inhaled β-agonists. Other respiratory medications 
were also used in similar proportions for all groups with the exception of ipratropium 
bromide. COPD patients were 21/2 times as likely to report the use of anticholinergic 
agent as asthma patients (Jackevicius  et al, 1997). And In our study most common drug 
prescribed to inpatients was Budesonide + Formoterol combinations 43.33% and less 
commonly prescribed drug was   Fluticasone + Salmeterol 3.33%.  
 
 Administration of corticosteroids either orally or by injection can be easily used 
to control asthma attack. Inhalation therapy is less effective and is not recommended. 
(Razi  et al, 2002). And In our study most common route of drug administration 
prescribed Dry Powder Inhaler (67.2%). 
 
  
 
 
 
 
 
 
 
 
 
 
Conclusion  
 
CONCLUSION 
 
Drug use is a complex process. In any country a large number of socio-cultural 
factors contribute to the way drugs are used. Hence drug utilization research is an 
essential part of pharmacoepidemiology as it describes the extent, nature and 
determinants of drug exposure. Drug utilization evaluation can be used for the 
description of drug use pattern; early signals of irrational use of drugs; interventions to 
improve drug use; quality control cycle and for continuous quality improvement. For the 
individual patient, the rational use of a drug implies the prescription of a well 
documented drug at an optimal dose, together with the correct information, at an 
affordable price. Drug utilization research in itself does not necessarily provide answers, 
but it contributes to rational drug use in important ways. 
 
Our study was on the prescribing pattern of the corticosteroids in COPD, Asthma 
and Allergic Rhinitis in the Pulmonology Department. The present study aims to answer 
the following questions such as how does the use of corticosteroids vary with 
demographic factors, like age, sex, socioeconomic status and locality of residence, What 
are the different types of steroids prescribed, its dose and route of administration, 
Difference in corticosteroids used in various diseases and how does the use of 
corticosteroids vary with severity of disease. 
 
In this present study, the first focuses was how the use of corticosteroids vary 
with the demographic profiles. In the present study focused both men and women in 
almost equal range and observed that males are more prone to the use of corticosteroids, 
use was maximum elderly persons. In the study population we find out that there is a 
statistically significant relationship exist between age (p<0.007), gender (p<0.016), 
locality of residence (p<0.023) & socioeconomic status (p<0.016) with the prescribing 
pattern of corticosteroids. 
 
The second priority was given to the different types of steroids prescribed, its 
dose and route of administration. Most common route of administration was dry powder 
inhaler (67.2%) followed by MDI (16.8%), Nasal spray (10.4%), and Oral (5.6%) 
respectively. Most commonly prescribed drug was Budesonide + Formoterol  
(78.4%)combination whereas Budesonide(2.4%)  alone was less commonly prescribed. 
Budesonide + Formoterol  200 mcg combination was given in 37 prescriptions and 400 
mcg was given in 61 prescriptions. 
 
The third focus of the present study is to identify the difference in corticosteroids 
used in various diseases. In the present study the total study populations were 
categorized into four group on the basis of diagnosis. It was given as Asthma, COPD, 
Allergic Rhinitis  & Allergic Rhinitis + Asthma. Median route of administration in 
Asthma , COPD and Allergic Rhinitis +Asthma prescription was dry powder inhaler 
33(80.48%), 21(58.33%), 10(60%) respectively. The most prominent route of 
administration was nasal spray in Allergic Rhinitis prescriptions. Median drug of 
administration in Asthma, COPD and Allergic Rhinitis +Asthma was Budesonide + 
Formoterol  36(87.80%) , 35(97.22%), 8(80%) respectively. The most prominent drug of 
administration was Mometasone furoate 13(61.90%) in Allergic Rhinitis. 
 
The final objective and the focus is to identify that how does the use of 
corticosteroids vary with severity of disease. Through the present study the investigator 
is able to recognize that there is a statistical significance in the use of corticosteroids with 
the severity of diseases like COPD (p<0.008) & Asthma (p<0.011). 
 
At last, the present study, was able to conclude that the prescription patterns of 
corticosteroids varied, based on the several factors such as age, sex, socio economic 
status and area of residence. In the current practice, Dry Powder Inhaler was the most 
common drug route and the Budesonide + Formoterol the most common prescribed drug 
of choice among the physicians. The present study also was able to recognize that there 
is a difference present in the drug prescriptions based on the severity of the disease 
conditions. 
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Appendix  
 
  
DATA ENTRY FORM 
 
Name of Patient: …………………………..       IP No: ……..………………………….. 
Place………………….       Age in years……     Sex M / F ……      
Married/Unmarried 
Occupation: ………………………………….      
 
1. C/O…………………………………………………………………………………… 
           
………………………………………………………………………………………… 
          
……………………………………………………………………………………………. 
 
2. Socio-Economic Status 
 
3. Past medical history     : 
………………………………………………………………………. 
                                               
.………………………………………………………………….....                                                                  
4. Past medication history: 
………………………………………………………….................... 
                                             
………………………………………………………………………. 
                                            
……………………………………………………………………….. 
                                          
……………......................................................................................... 
5. 
DIAGNOSIS……………………………………………………………………………… 
 
FVC    
FEV1    
FEV1%FVC    
Alcohol YES NO Ex-Alcoholic 
Smoking YES NO Ex-Smoker 
6. CURRENT MEDICATIONS:            
 
DRUG 
 
DOSAGE 
 
FREQUENCY 
 
DURATION 
 
ROUTE OF 
ADMINISTRATION 
     
     
     
     
7. DURING THE TREATMENT:            
 
DRUG 
 
DOSAGE 
 
FREQUENCY 
 
DURATION 
 
ROUTE OF 
ADMINISTRATION 
     
     
     
     
     
     
     
     
 
 
 
